About
Drew is a managing director & Co-Founder at Enterprise Partners where he leads the life science practice. Drew focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. Drew has served on over 25 public and private boards including Adeza Biomedical, NuVasive, Corixa Corp., Ligand Pharmaceuticals, Nanogen, Inc., and Discovery Partners. Drew currently sits on the boards of current Enterprise portfolio companies including: Scoperta, Inc., Ascenta Therapeutics, Celladon, Celula, Complete Genomics, Ophthonix, TargeGen and Scoperta, Inc. Prior to joining Enterprise Partners in 1987, Drew was a physician and entrepreneur. While still a medical student at Northwestern University, Drew developed a drug delivery device and licensed it to Eli Lilly. Subsequently Drew joined Lilly as consultant while completing his internship at the University of California Irvine. Drew holds a B.S. from Occidental College and an M.D. from Northwester
Position in the VCSift Database
- • 2 investors at Enterprise Partners are tracked.
- • 1,801 investors hold the Managing Director & Co-Founder role in VCSift. Drew Senyei is one of them.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Diego, US
Contact Information
Find more investors like Drew
Search Investors